

## SUPPLEMENTARY TABLES

**Supplementary Table 1. Inhibitors used in this study.**

Inhibitors	Name	Source	Catalog No.	Concentration
<b>MEK</b>	PD98059	Sigma (St. Louis, MO, USA)	P215-1MG	10 $\mu$ M
<b>ERK</b>	FR180204	Santa Cruz Biotechnology, Dallas, TX, USA	SC-203945	10 $\mu$ M
<b><math>\kappa</math>B</b>	PDTC	Sigma (St. Louis, MO, USA)	P8765-1G	3 $\mu$ M
<b><math>\kappa</math>B</b>	TPCK	Sigma (St. Louis, MO, USA)	T4376-100MG	3 $\mu$ M

**Supplementary Table 2. siRNA used in this study.**

Gene	Species	Source	Catalog no
<b>MEK</b>	Human	Dharmacon (2650 Crescent Dr, Lafayette, USA)	L00357100
<b>ERK</b>	Human	Dharmacon (2650 Crescent Dr, Lafayette, USA)	L00355500
<b>p65</b>	Human	Dharmacon (2650 Crescent Dr, Lafayette, USA)	L-003533-00-0005
<b>Control</b>	Human	Dharmacon (2650 Crescent Dr, Lafayette, USA)	D-001810-10-05

**Supplementary Table 3. Primers used in this study.**

Gene	Forward	Reverse
<b><i>VEGF-C</i></b>	CACTTGCTGGGCTTCTTCT	CACAGACCGTAACTGCTCCT
<b><i>GAPD-H</i></b>	AATGGACAACCTGGTCGTGGA	CCCTCCAGGGATCTGTTTG

**Supplementary Table 4. Antibodies used in this study.**

Protein	Dilution	Catalog No.	Source
<b>VEGF-C</b>	1:3000	SC-9047	Santa Cruz Biotechnology, Dallas, TX, USA
<b>Visfatin</b>	1:3000	ab45890	Abcam, Shanghai, China
<b><math>\beta</math>-actin</b>	1:3000	SC-58673	Santa Cruz Biotechnology, Dallas, TX, USA
<b>p-MEK1/2</b>	1:3000	#9121	Cell Signaling (Danvers, MA, USA)
<b>MEK</b>	1:3000	#9122	Cell Signaling (Danvers, MA, USA)
<b>p-ERK</b>	1:3000	SC-7383	Santa Cruz Biotechnology, Dallas, TX, USA
<b>ERK</b>	1:3000	SC-1647	Santa Cruz Biotechnology, Dallas, TX, USA
<b>p-p65</b>	1:3000	SC-101752	Santa Cruz Biotechnology, Dallas, TX, USA
<b>p65</b>	1:3000	SC-8008	Santa Cruz Biotechnology, Dallas, TX, USA